Literature DB >> 21642015

Ratio of visceral to subcutaneous fat area is a biomarker of complicated Crohn's disease.

Bara Erhayiem1, Rajpal Dhingsa, Christopher J Hawkey, Venkataraman Subramanian.   

Abstract

BACKGROUND & AIMS: Fat wrapping and mesenteric hypertrophy are characteristics of Crohn's disease (CD). In patients with CD, mesenteric adipose tissue releases higher levels of adiponectin, which could up-regulate production of tumor necrosis factor-α and increase the risk for aggressive disease. We investigated whether a higher ratio of visceral to subcutaneous fat was associated with complicated (fistulating or stricturing) CD.
METHODS: We identified patients with a confirmed diagnosis of CD who had computed tomography scans of their abdomens (n = 50). Areas of subcutaneous and visceral fat were measured in 1 cross-sectional scan that was taken at the level of the umbilicus. The mesenteric fat index (MFI), defined as the ratio of areas of visceral to subcutaneous fat, was compared between patients with complicated (strictures and fistulas) and inflammatory CD.
RESULTS: The mean age of the patients with complications (n = 29) was 49.3 ± 15.6 years, and in patients with inflammatory CD (n = 21) it was 37.7 ± 19.1 years. The MFI was significantly higher (P = .001) in patients with complicated disease (0.67 ± 0.29) than in those with uncomplicated disease (0.23 ± 0.10) and was the only variable that remained significantly different on multivariate analysis. The area under the receiver operating curve for the MFI was 0.95 (95% confidence interval, 0.89-1.0), and an MFI of 0.29 identified patients with complicated CD with 93% sensitivity and 81% specificity.
CONCLUSIONS: A high ratio of areas of visceral to subcutaneous fat (MFI) is a marker of aggressive CD. Further studies are needed to determine the roles of adipose tissue in pathogenesis of CD.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642015     DOI: 10.1016/j.cgh.2011.05.005

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  41 in total

1.  Abdominal Fat Accumulation, as Measured by Computed Tomography, Increases the Risk of Ischemic Colitis: A Retrospective Case-Control Study.

Authors:  Tomonori Aoki; Naoyoshi Nagata; Kayo Sakamoto; Tomohiro Arai; Ryota Niikura; Takuro Shimbo; Masafumi Shinozaki; Katsunori Sekine; Hidetaka Okubo; Kazuhiro Watanabe; Toshiyuki Sakurai; Chizu Yokoi; Junichi Akiyama; Mikio Yanase; Masashi Mizokami; Mitsuhiko Noda; Naomi Uemura
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

2.  Obesity Is Associated with Increased Risk of Colectomy in Inflammatory Bowel Disease Patients Hospitalized with Clostridium difficile Infection.

Authors:  Manish P Shrestha; Sasha Taleban
Journal:  Dig Dis Sci       Date:  2018-12-19       Impact factor: 3.199

3.  Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.

Authors:  R W Stidham; A K Waljee
Journal:  Aliment Pharmacol Ther       Date:  2017-06       Impact factor: 8.171

Review 4.  Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.

Authors:  Siddharth Singh; Parambir S Dulai; Amir Zarrinpar; Sonia Ramamoorthy; William J Sandborn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

5.  Visceral Adiposity, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.

Authors:  Kimberley W J Van Der Sloot; Amit D Joshi; Danielle R Bellavance; Katherine K Gilpin; Kathleen O Stewart; Paul Lochhead; John J Garber; Cosmas Giallourakis; Vijay Yajnik; Ashwin N Ananthakrishnan; Behrooz Z Alizadeh; Ramnik J Xavier; Hamed Khalili
Journal:  Inflamm Bowel Dis       Date:  2017-01       Impact factor: 5.325

6.  Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Authors:  Siddharth Singh; James Proudfoot; Ronghui Xu; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

7.  Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease.

Authors:  Avegail Flores; Ezra Burstein; Daisha J Cipher; Linda A Feagins
Journal:  Dig Dis Sci       Date:  2015-03-24       Impact factor: 3.199

8.  Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis.

Authors:  D Q Holt; P Varma; B J G Strauss; A S Rajadurai; G T Moore
Journal:  Eur J Clin Nutr       Date:  2017-02-22       Impact factor: 4.016

9.  Toll-like receptor 4, F4/80 and pro-inflammatory cytokines in intestinal and mesenteric fat tissue of Crohn's disease.

Authors:  Raquel F Leal; Marciane Milanski; Maria de Lourdes S Ayrizono; Andressa Coope; Viviane S Rodrigues; Mariana Portovedo; Luiza M F Oliveira; João J Fagundes; Cláudio S R Coy; Lício A Velloso
Journal:  Int J Clin Exp Med       Date:  2013-01-26

10.  Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease.

Authors:  V S Rodrigues; M Milanski; J J Fagundes; A S Torsoni; M L S Ayrizono; C E C Nunez; C B Dias; L R Meirelles; S Dalal; C S R Coy; L A Velloso; R F Leal
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.